NBIX Neurocrine Biosciences (NBIX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0000914475
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
473
13F, latest reported quarter
Conversions, 180 days
28
Codes C/M, not in net · $19.1M priced
What the filings say about NBIX
Insiders, 180 days
-$63.3M net sold
11 sellers · 10% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-06-17
Planned sales (Form 144), 90 days
$1.4M
3 notices
Neurocrine Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, NEUROCRINE BIOSCIENCES INC insiders sold a net $63.3M of stock across 365 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Feb 13, 2025.
- The trade is 5.4% of the 42,808 shares held after it.
- 2 other insiders sold within 30 days.
- 473 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer ABERNETHY MATT sold about $363.3K of NBIX under a 10b5-1 plan on Sep 14, 2026; 2 other insiders sold within 30 days and 473 funds added in the latest 13F quarter.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on May 26, 2026.
- The trade is 9.5% of the 8,722 shares held after it.
- 2 other insiders sold within 30 days.
- 473 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Corp. Affairs Officer Boyer David W. sold about $130.1K of NBIX under a 10b5-1 plan on Sep 14, 2026; 2 other insiders sold within 30 days and 473 funds added in the latest 13F quarter.Context
- 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Nov 28, 2025.
- The trade is 3.3% of the 64,408 shares held after it.
- 2 other insiders sold within 30 days.
- 473 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer BENEVICH ERIC sold about $333.0K of NBIX under a 10b5-1 plan on Sep 9, 2026; 2 other insiders sold within 30 days and 473 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 4, 2026.
- The trade is 78.7% of the 1,588 shares held after it.
- 2 other insiders sold within 30 days.
- 473 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Norwalk Leslie V sold about $227.5K of NBIX on Jul 28, 2026; 2 other insiders sold within 30 days and 473 funds added in the latest 13F quarter.Context
- 34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Jul 9, 2026.
- The trade is 26.9% of the 16,225 shares held after it.
- 2 other insiders sold within 30 days.
- 473 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Regulatory Officer Delaet Ingrid sold about $790.5K of NBIX on Jul 10, 2026; 2 other insiders sold within 30 days and 473 funds added in the latest 13F quarter.365 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$63.3M over 180 days
-$826.4K over 90 days
below 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
473 funds bought in last quarter
more than 97% of Pharma & Biotech
Revenue
+21.4% year over year
more than 68% of Pharma & Biotech
Margin
16.7% net margin
more than 86% of Pharma & Biotech
Buybacks
$66.0M repurchased, FY to 2026-06-30
more than 60% of Pharma & Biotech
Short interest
6.4% of the float short (float per yahoo 2026-10-27) · 4.5 days to cover · settled 2026-10-15
more than 59% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NBIX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+1.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NBIX: institutional holders (13F)
13F holdings, latest reported quarter
13,711,607 sh
$2.3B
6,398,674 sh
$1.1B
5,584,707 sh
$941.2M
4,974,083 sh
$838.3M
4,545,339 sh
$766.0M
Congress trades in NBIX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-06-17 · disclosed 57 days later
$1,001 - $15,000
Bought 2025-06-11 · disclosed 63 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NBIX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
MATTHEW C ABERNETHY
Filed 2026-09-14
$361.0K
DAVID WARREN BOYER
Filed 2026-09-14
$736.4K
ERIC BENEVICH
Filed 2026-09-09
$334.2K
INGRID DELAET
Filed 2026-07-10
$788.5K
DARIN LIPPOLDT
Filed 2026-07-09
$1.8M
NBIX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$1.9M position · as of 2026-06-30
4.4%
Quantified Common Ground Fund
$4.6M position · as of 2026-06-30
3.8%
First Trust NYSE Arca Biotechnology Index Fund
$99.2M position · as of 2026-06-30
3.5%
AlphaCentric Life Sciences and Healthcare Fund
$1.6M position · as of 2026-06-30
3.5%
Baird Small/Mid Cap Growth Fund
$2.5M position · as of 2026-06-30
3.3%
Impax Small Cap Fund
$27.0M position · as of 2026-06-30
2.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
41 registered trials, 19 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
20
Phase 2
6 active
17
Phase 3
12 active
2
Phase 4
1 active
1
Not applicable
0 active
What changed recently
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive
2026-09-19 · Completion moved 2027-01 → 2028-06
Phase 4
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participa
2026-09-10 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Neurocrine Biosciences Pac Inc.
Cycle 2026 · $169K spent
$93.5K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Kevin C. Gorman, Ph.D
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.9M
$6.0M
$6.9M
+48%
+25%
2023
$15.8M
$12.3M
$6.3M
+37%
-6%
2022
$11.9M
$21.9M
$5.2M
+25%
-10%
2021
$14.1M
$4.5M
$6.4M
-11%
+0%
2020
$13.9M
$8.2M
$6.5M
-11%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $63.3M sold by insiders over 180 days, 473 funds added last quarter, $1.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
NBIX financials
Revenue growth
+21.4%
XBRL, annual
Net margin
16.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.4B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NBIX
| FY Dec 2025 | $2.9B |
| FY Dec 2024 | $2.4B |
| FY Dec 2023 | $1.9B |
| FY Dec 2022 | $1.5B |
| FY Dec 2021 | $1.1B |
| Jun 2026 | $959.0M |
| Mar 2026 | $814.5M |
| Dec 2025 | $805.5M |
| Sep 2025 | $794.9M |
| Jun 2025 | $687.5M |
| Mar 2025 | $572.6M |
| Dec 2024 | $627.7M |
| Sep 2024 | $622.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+20.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NBIX
| FY Dec 2025 | +16.7% |
| FY Dec 2024 | +14.5% |
| FY Dec 2023 | +13.2% |
| FY Dec 2022 | +10.4% |
| FY Dec 2021 | +7.9% |
| Jun 2026 | +15.1% |
| Mar 2026 | +24.3% |
| Dec 2025 | +19.1% |
| Sep 2025 | +26.4% |
| Jun 2025 | +15.6% |
| Mar 2025 | +1.4% |
| Dec 2024 | +16.4% |
| Sep 2024 | +20.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$870.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NBIX
| FY Dec 2025 | $748.7M |
| FY Dec 2024 | $557.2M |
| FY Dec 2023 | $361.6M |
| FY Dec 2022 | $322.9M |
| FY Dec 2021 | $233.1M |
| Jun 2026 | $128.6M |
| Mar 2026 | $136.7M |
| Dec 2025 | $390.8M |
| Sep 2025 | $214.3M |
| Jun 2025 | $89.5M |
| Mar 2025 | $54.1M |
| Dec 2024 | $235.2M |
| Sep 2024 | $149.9M |
At each fiscal year end
Single quarter
Debt to equity
0.05x
long-term debt only, 2023-03-31 (39 months older than the period end); equity 2026-06-30
Debt to equity NBIX
| FY Dec 2025 | 0.05x |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | 0.08x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.24x |
| Jun 2026 | 0.05x |
| Mar 2026 | 0.05x |
| Dec 2025 | 0.05x |
| Sep 2025 | 0.06x |
| Jun 2025 | 0.06x |
| Mar 2025 | 0.07x |
| Dec 2024 | 0.07x |
| Sep 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
5.30x
TTM operating cash flow over long-term debt only, 2023-03-31 (39 months older than the period end)
Cash flow to debt NBIX
| FY Dec 2025 | 4.62x |
| FY Dec 2024 | 3.51x |
| FY Dec 2023 | 2.30x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.77x |
| Jun 2026 | 5.30x |
| Mar 2026 | 5.10x |
| Dec 2025 | 4.62x |
| Sep 2025 | 3.76x |
| Jun 2025 | 3.35x |
| Mar 2025 | 3.13x |
| Dec 2024 | 3.51x |
| Sep 2024 | 2.81x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+22.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NBIX
| FY Dec 2025 | +16.4% |
| FY Dec 2024 | +14.2% |
| FY Dec 2023 | +12.7% |
| FY Dec 2022 | +10.0% |
| FY Dec 2021 | +7.2% |
| Jun 2026 | +22.1% |
| Mar 2026 | +22.5% |
| Dec 2025 | +16.4% |
| Sep 2025 | +15.0% |
| Jun 2025 | +13.4% |
| Mar 2025 | +12.4% |
| Dec 2024 | +14.2% |
| Sep 2024 | +16.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+15.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NBIX
| FY Dec 2025 | +11.5% |
| FY Dec 2024 | +9.8% |
| FY Dec 2023 | +8.9% |
| FY Dec 2022 | +7.0% |
| FY Dec 2021 | +4.7% |
| Jun 2026 | +15.3% |
| Mar 2026 | +15.6% |
| Dec 2025 | +11.5% |
| Sep 2025 | +11.0% |
| Jun 2025 | +9.7% |
| Mar 2025 | +8.5% |
| Dec 2024 | +9.8% |
| Sep 2024 | +12.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+19.5%
operating income after a 25.0% effective tax rate, over long-term debt only, 2023-03-31 (39 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital NBIX
| FY Dec 2025 | +16.0% |
| FY Dec 2024 | +17.1% |
| FY Dec 2023 | +10.0% |
| FY Dec 2022 | +14.5% |
| FY Dec 2021 | +6.9% |
| Jun 2026 | +19.5% |
| Mar 2026 | +19.3% |
| Dec 2025 | +16.0% |
| Sep 2025 | +13.9% |
| Jun 2025 | +12.7% |
| Mar 2025 | +13.9% |
| Dec 2024 | +17.1% |
| Sep 2024 | +19.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+20.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NBIX
| FY Dec 2025 | +17.4% |
| FY Dec 2024 | +19.6% |
| FY Dec 2023 | +11.3% |
| FY Dec 2022 | +13.6% |
| FY Dec 2021 | +6.1% |
| Jun 2026 | +20.3% |
| Mar 2026 | +21.8% |
| Dec 2025 | +17.4% |
| Sep 2025 | +16.3% |
| Jun 2025 | +15.8% |
| Mar 2025 | +16.7% |
| Dec 2024 | +19.6% |
| Sep 2024 | +22.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
21.39x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing NBIX
| FY Dec 2025 | 30.44x |
| FY Dec 2024 | 41.49x |
| FY Dec 2023 | 54.00x |
| FY Dec 2022 | 77.56x |
| FY Dec 2021 | 92.58x |
| Jun 2026 | 24.71x |
| Mar 2026 | 20.30x |
| Dec 2025 | 30.44x |
| Sep 2025 | 33.58x |
| Jun 2025 | 37.19x |
| Mar 2025 | 37.49x |
| Dec 2024 | 41.49x |
| Sep 2024 | 30.73x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$14.7B
market value at close 2026-10-26 on 2026-07-22 shares, plus long-term debt only, 2023-03-31 (39 months older than the period end), minus cash 2026-06-30
Enterprise value NBIX
| FY Dec 2025 | $13.6B |
| FY Dec 2024 | $13.8B |
| FY Dec 2023 | $12.9B |
| FY Dec 2022 | $11.2B |
| FY Dec 2021 | $8.1B |
| Jun 2026 | $16.8B |
| Mar 2026 | $13.1B |
| Dec 2025 | $13.6B |
| Sep 2025 | $13.8B |
| Jun 2025 | $12.3B |
| Mar 2025 | $11.0B |
| Dec 2024 | $13.8B |
| Sep 2024 | $11.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield NBIX
| FY Dec 2025 | +5.3% |
| FY Dec 2024 | +4.0% |
| FY Dec 2023 | +2.8% |
| FY Dec 2022 | +2.8% |
| FY Dec 2021 | +2.9% |
| Jun 2026 | +5.1% |
| Mar 2026 | +6.3% |
| Dec 2025 | +5.3% |
| Sep 2025 | +4.3% |
| Jun 2025 | +4.3% |
| Mar 2025 | +4.5% |
| Dec 2024 | +4.0% |
| Sep 2024 | +3.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.21x
P/E over trailing EPS growth of 102%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing NBIX
| FY Dec 2025 | 0.73x |
| FY Dec 2024 | 1.19x |
| FY Dec 2023 | 0.92x |
| FY Dec 2022 | 1.15x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.24x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.73x |
| Sep 2025 | 2.93x |
| Jun 2025 | 24.77x |
| Mar 2025 | n/a |
| Dec 2024 | 1.19x |
| Sep 2024 | 0.31x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.9B | $2.4B | $1.9B | $1.5B |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M |
| EPS (diluted) | 4.67 | 3.29 | 2.47 | 1.56 |
| Operating cash flow | $782.7M | $595.4M | $389.9M | $339.4M |
| Cash | $713.0M | $233.0M | $251.1M | $262.9M |
| Long-term debt | n/a | n/a | n/a | $0 |
| Buybacks | $167.7M | $300.0M | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
NBIX Stock Sonar score 6/7 axes
Find similar shapesCompareNBIX ranks highest on institutional and government (95th percentile) and profitability (83rd), and lowest on insider conviction (2nd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NBIX filings, in plain words
Are Neurocrine Biosciences insiders buying or selling NBIX?
In the 180 days to 2026-10-28, Neurocrine Biosciences insiders were net sellers, a net $63.3M across purchases and sales reported on Form 4, by 11 sellers.
Have members of Congress traded NBIX?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Lisa McClain dated 2025-06-17.
Are there planned insider sales of NBIX?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.4M of stock; the latest, by MATTHEW C ABERNETHY, was filed 2026-09-14.
Read the full summary
In the 180 days to 2026-10-28, Neurocrine Biosciences insiders were net sellers of NBIX, a net $63.3M across purchases and sales reported on Form 4 by 11 sellers. 10% of the 30 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in NBIX, none in the last year; the latest on record is a sale by Lisa McClain dated 2025-06-17. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
